RxDoctor Payments DataLook up a doctor →

Patricia de Jesus

Neurology · Caguas, PRNPI 1639379266

Payments from drug & device makers

$310,260in general payments, 2019–2025

Across 959 payments — averaging $323.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$121K
  • EMD Serono, Inc.$64K
  • Genentech USA, Inc.$36K
  • TG Therapeutics, Inc.$27K
  • Bristol Myers Squibb$23K
  • Sanofi$18K
  • plus $20K from 18 others

What the payments were for

  • Consulting fees$50,78516%
  • Speaking & faculty fees$222,83372%
  • Travel & lodging$9,9063%
  • Food & beverage$26,4989%
  • Education$1780%
  • Gifts$600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$310,260 in reported general payments places this provider in the 95th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab215$1,970,541
VumerityDiroximel Fumarate67$580,057
TecfideraDimethyl Fumarate58$541,471
AubagioTeriflunomide53$494,020
GilenyaFingolimod Hcl37$389,848
ZeposiaOzanimod Hydrochloride41$363,857
AmpyraDalfampridine83$361,189
Avonex Pen (4 Pack)Interferon Beta-1a35$291,689
EnspryngSatralizumab-Mwge13$222,396
MayzentSiponimod20$194,195
TysabriNatalizumab17$140,872
CopaxoneGlatiramer Acetate11$79,124
Emgality PenGalcanezumab-Gnlm82$59,744
Dalfampridine ErDalfampridine327$55,108
Glatiramer Acetate15$38,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Tecfidera, Tysabri$120,937$1,262,400142 claims
NovartisGilenya, Mayzent$12,778$584,04257 claims
SanofiAubagio$18,117$494,02053 claims
E.r. Squibb & Sons, L.L.C.Zeposia$1,935$363,85741 claims
Genentech USA, Inc.Enspryng$35,666$222,39613 claims
Teva Pharmaceuticals USA, Inc.Copaxone$202$79,12411 claims
AbbVieUbrelvy$603$27,13020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 129 neurology providers in Puerto Rico.

Other neurology in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →